国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2009年
15期
914-916
,共3页
杨秀娜%陈刚%孙磊%杨昆%郭春阳%杨君莉%郭新宁
楊秀娜%陳剛%孫磊%楊昆%郭春暘%楊君莉%郭新寧
양수나%진강%손뢰%양곤%곽춘양%양군리%곽신저
真菌变应原疫苗%特异性免疫治疗%哮喘
真菌變應原疫苗%特異性免疫治療%哮喘
진균변응원역묘%특이성면역치료%효천
Fungi allergen vaecine%Specific immunotherapy%Asthma
目的 评价真菌疫苗特异性免疫治疗变应性支气管哮喘(简称哮喘)的临床疗效.方法 选择60例真菌过敏的轻、中度哮喘患者临床观察1年,治疗组(36例)和对照组(24例)分别皮下注射真菌变应原疫苗和盐酸组胺.观察治疗前后症状评分、用药计分、PD20-FEV1、PEF、FEV1pred%等指标.并进行统计分析.结果 两组治疗后症状评分均有所下降,但差异无统计学意义;与治疗前比较治疗组补救药物计分下降,PD20-FEV1增加,差异有统计学意义(P<0.01);两组PEF、FEV1pred%较治疗前差异均无统计学意义.治疗期间未发生一例严重不良反应事件.结论 对轻至中度的哮喘患者用真菌变应原疫苗进行特异性免疫治疗有效、安全.
目的 評價真菌疫苗特異性免疫治療變應性支氣管哮喘(簡稱哮喘)的臨床療效.方法 選擇60例真菌過敏的輕、中度哮喘患者臨床觀察1年,治療組(36例)和對照組(24例)分彆皮下註射真菌變應原疫苗和鹽痠組胺.觀察治療前後癥狀評分、用藥計分、PD20-FEV1、PEF、FEV1pred%等指標.併進行統計分析.結果 兩組治療後癥狀評分均有所下降,但差異無統計學意義;與治療前比較治療組補救藥物計分下降,PD20-FEV1增加,差異有統計學意義(P<0.01);兩組PEF、FEV1pred%較治療前差異均無統計學意義.治療期間未髮生一例嚴重不良反應事件.結論 對輕至中度的哮喘患者用真菌變應原疫苗進行特異性免疫治療有效、安全.
목적 평개진균역묘특이성면역치료변응성지기관효천(간칭효천)적림상료효.방법 선택60례진균과민적경、중도효천환자림상관찰1년,치료조(36례)화대조조(24례)분별피하주사진균변응원역묘화염산조알.관찰치료전후증상평분、용약계분、PD20-FEV1、PEF、FEV1pred%등지표.병진행통계분석.결과 량조치료후증상평분균유소하강,단차이무통계학의의;여치료전비교치료조보구약물계분하강,PD20-FEV1증가,차이유통계학의의(P<0.01);량조PEF、FEV1pred%교치료전차이균무통계학의의.치료기간미발생일례엄중불량반응사건.결론 대경지중도적효천환자용진균변응원역묘진행특이성면역치료유효、안전.
Objective To evaluate the clinical efficacy and safety of specific immunotherapy(SIT) with fungi allergen vaccine on allergic bronchial asthma(asthma). Methods Sixty patients of mild to moderate asthma who were allergic to fungi allergen, were randomly allocated to the active group ( n = 36) and the control group ( n = 24) were observed. The active group received SIT with a standardized fungi allergen vaccine,while the control group received a placebo containing histamine dihydrochlo-ride by subcutaneous injections for a year. Results The symptom scores in a year between the active group and the control group were no significant difference comparing with the year before. The mean daily medication scores in a year were significant lower than those of the year before, while the control group did not show significant difference. A significant difference was found in provoking dose dcreasing FEV1by 200% (PD20-FEV1) between the active group and the control group. After 1-year treatment,no significant differences were found in morning and evening peak expirating flow, expiratory volume in one second of predicted value (FEV1 pred%) between the active group and the control group. No any severe systemic therapy adverse reaction was shown in the study. Conclusions One year specific immunotherapy with standardized fungi allergen vaccine significantly improved symptoms and reduced medication use in mild to moderate allergic asthmatic patients. SIT also reduced brochial hyperreactivity. SIT with standardized fungi allergen vaccine is a safe treatement.